The Global Adrenal Corticosteroid Inhibitors Market to grow from USD 2.23 billion in 2022 to USD 5.78 billion by 2030, at a CAGR of 12.65%.

PUNE, MAHARASHTRA, INDIA , November 14, 2023 /EINPresswire.com/ -- The "Adrenal Corticosteroid Inhibitors Market by Drug (Aminoglutethimide, Levoketoconazole, Metyrapone), Treatment Type (Breast Cancer, Cushing's Syndrome, Prostate Cancer), Distribution Channel, End-user - Global Forecast 2023-2030" report has been added to 360iResearch.com's offering.

The Global Adrenal Corticosteroid Inhibitors Market to grow from USD 2.23 billion in 2022 to USD 5.78 billion by 2030, at a CAGR of 12.65%.

Request a Free Sample Report @ https://www.360iresearch.com/library/intelligence/adrenal-corticosteroid-inhibitors?utm_source=einpresswire&utm_medium=referral&utm_campaign=sample

Adrenal corticosteroid inhibitors are a class of pharmaceutical compounds designed to suppress the production or inhibitory action of cortisol and other corticosteroids within the body. Corticosteroids are a group of hormones that are primarily produced by the adrenal glands that are located above each kidney. These hormones regulate numerous physiological processes such as immune response, inflammation, stress, metabolism, and blood pressure. Prevalence of endocrine diseases, including obesity, type 2 diabetes mellitus, and polycystic ovary syndrome, have contributed to a higher need for Adrenal corticosteroid inhibitor-based therapies. However, regulatory hurdles pertaining to drug approval processes can impose significant time delays and financial costs on pharmaceutical companies seeking approval for new drugs or expanded indications. Furthermore, the ongoing development of new drugs with improved efficacy, specificity, and reduced side effects is anticipated to accelerate the use of adrenal corticosteroid inhibitors by the end-use sectors globally.

Treatment Type: Increasing use of adrenal corticosteroid inhibitors for treating cushing's syndrome
Adrenal corticosteroid inhibitors are utilized in the treatment of hormone-receptor-positive (HR+) metastatic breast cancer. The need for these inhibitors arises when patients become resistant to aromatase inhibitors, which are the first line of treatment for HR+ breast cancer. Adrenal corticosteroid inhibitors play a critical role in managing Cushing's syndrome, a hormonal disorder caused by prolonged exposure to high levels of cortisol. These inhibitors aim to reduce cortisol production and alleviate symptoms associated with cortisol excess, such as obesity, fatigue, and hypertension. Advanced prostate cancer often progresses despite initial hormone therapy due to the continued production of androgen hormones. Adrenal corticosteroid inhibitors, such as abiraterone acetate, are combined with prednisone, a corticosteroid drug, to suppress androgen production and limit cancer growth.

Distribution Channel: Evolving online distribution channel for adrenal corticosteroid inhibitors
In the distribution of adrenal corticosteroid inhibitors, hospital pharmacies play a crucial role, as they cater to patients admitted in hospitals and clinics. These medical facilities usually have an in-house pharmacy, ensuring the accessibility and availability of medications, including adrenal corticosteroid inhibitors. Hospital pharmacies mainly procure drugs directly from manufacturers or suppliers. With the growing preference for home delivery services, online pharmacies have rapidly gained popularity in recent years due to increasing internet penetration worldwide. Online pharmacies offer convenience through door-to-door deliveries while maintaining quality assurance by sourcing directly from manufacturers or authorized distributors. However, there is a need to be cautious regarding counterfeit drugs sold on some unregulated e-commerce websites. Retail pharmacies remain an integral part of the distribution channel landscape for adrenal corticosteroid inhibitors due to their widespread presence across residential areas worldwide. They serve walk-in customers who require over-the-counter or prescription-based medications promptly.

Drug: Burgeoning utilization of osilodrostat drug owing to its long-term treatment option for diseases
Aminoglutethimide is an older-generation adrenal steroid inhibitor that stops the conversion of cholesterol to pregnenolone in the adrenal cortex, thereby reducing cortisol production. Levoketoconazole is a novel investigational drug and shows results in treating endogenous Cushing's syndrome by inhibiting cortisol synthesis by blocking multiple enzymes involved in steroidogenesis. Metyrapone is an adrenal corticosteroid inhibitor that inhibits 11β-hydroxylase, an enzyme in cortisol production. This drug is used as a short-term treatment option for patients experiencing acute episodes of Cushing's syndrome or as a diagnostic tool to determine cortisol responsiveness. Osilodrostat is a potent oral inhibitor of 11β-hydroxylase that has demonstrated rapid and sustained reductions in mean urinary-free cortisol levels in patients with Cushing's disease.

End-user: Significant adoption of adrenal corticosteroid inhibitors in specialty centers
Hospitals remain a primary setting for administering adrenal corticosteroid inhibitors owing to their ability to provide comprehensive care with access to advanced diagnostic tools and emergency intervention if required. Patients with severe or life-threatening conditions, such as adrenal carcinoma or those requiring surgery, often receive their inhibitor treatments in a hospital setting. Specialty centers focus on providing specialized care to patients with specific medical conditions. In the context of adrenal corticosteroid inhibitors, these centers cater to patients with rare endocrine disorders where expert knowledge and experience are vital in managing these complex cases.

Regional Insights:
The adrenal corticosteroid inhibitors market is evolving in the Americas owing to the growing awareness of Addison's disease, Cushing's syndrome, and other adrenocortical disorders, increased research funding from the and collaboration with major pharmaceutical companies facilitating advanced clinical trials and novel drug development. In EU countries, the demand for adrenal corticosteroid inhibitors has escalated due to increased awareness about early detection and effective treatment options for adrenal diseases. The EMEA region represents a significant opportunity for adrenal corticosteroid inhibitor manufacturers as governments invest in improving healthcare infrastructure, raising public health awareness, and promoting clinical research activities. Adrenal corticosteroid inhibitors are growing in the APAC region, with pharmaceutical companies developing novel inhibitors through robust R&D strategies and government policies encouraging investment in biopharmaceutical manufacturing plants. Furthermore, the emergence of online pharmacy and distribution platforms is anticipated to expand the distribution and improve the treatment outcomes of adrenocortical medical conditions.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Adrenal Corticosteroid Inhibitors Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in the Adrenal Corticosteroid Inhibitors Market. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

Key Company Profiles:

The report delves into recent significant developments in the Adrenal Corticosteroid Inhibitors Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adooq Bioscience LLC, Cayman Chemical Company, Crinetics Pharmaceuticals, Inc., Eli Lilly and Company, Enzo Life Sciences, Inc., Hefei Home Sunshine Pharmaceutical Technology Co., Ltd., HRA Pharma Rare Diseases SAS by Perrigo Company plc, MedChemExpress, Merck KGaA, Novartis AG, Orphagen Pharmaceuticals, Pfizer Inc., Sparrow Pharmaceuticals Inc., Steris Healthcare PVT Ltd, Tocris Bioscience by Bio-Techne Corporation, and Xeris Biopharma Holdings, Inc..

Inquire Before Buying @ https://www.360iresearch.com/library/intelligence/adrenal-corticosteroid-inhibitors?utm_source=einpresswire&utm_medium=referral&utm_campaign=inquire

Market Segmentation & Coverage:

This research report categorizes the Adrenal Corticosteroid Inhibitors Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Drug, market is studied across Aminoglutethimide, Levoketoconazole, Metyrapone, and Osilodrostat. The Levoketoconazole is projected to witness significant market share during forecast period.

Based on Treatment Type, market is studied across Breast Cancer, Cushing's Syndrome, and Prostate Cancer. The Breast Cancer is projected to witness significant market share during forecast period.

Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy. The Online Pharmacy is projected to witness significant market share during forecast period.

Based on End-user, market is studied across Hospitals and Speciality Centres. The Speciality Centres is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded largest market share of 37.23% in 2022, followed by Americas.

Key Topics Covered:

1. Preface
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
6. Adrenal Corticosteroid Inhibitors Market, by Drug
7. Adrenal Corticosteroid Inhibitors Market, by Treatment Type
8. Adrenal Corticosteroid Inhibitors Market, by Distribution Channel
9. Adrenal Corticosteroid Inhibitors Market, by End-user
10. Americas Adrenal Corticosteroid Inhibitors Market
11. Asia-Pacific Adrenal Corticosteroid Inhibitors Market
12. Europe, Middle East & Africa Adrenal Corticosteroid Inhibitors Market
13. Competitive Landscape
14. Competitive Portfolio
15. Appendix

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Adrenal Corticosteroid Inhibitors Market?
2. Which are the products/segments/applications/areas to invest in over the forecast period in the Adrenal Corticosteroid Inhibitors Market?
3. What is the competitive strategic window for opportunities in the Adrenal Corticosteroid Inhibitors Market?
4. What are the technology trends and regulatory frameworks in the Adrenal Corticosteroid Inhibitors Market?
5. What is the market share of the leading vendors in the Adrenal Corticosteroid Inhibitors Market?
6. What modes and strategic moves are considered suitable for entering the Adrenal Corticosteroid Inhibitors Market?

Read More @ https://www.360iresearch.com/library/intelligence/adrenal-corticosteroid-inhibitors?utm_source=einpresswire&utm_medium=referral&utm_campaign=analyst

Mr. Ketan Rohom
360iResearch
+1 530-264-8485
ketan@360iresearch.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.